Phase 3 Study of Recombinant Factor IX Fc Fusion Protein in Hemophilia B

Abstract

Prophylactic rFIXFc, administered every 1 to 2 weeks, resulted in low annualized bleeding rates in patients with hemophilia B. (Funded by Biogen Idec; ClinicalTrials.gov number, NCT01027364.).